TrialCancer2022

Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.

Heidi V Russell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.